These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38810731)

  • 1. Age-Related Clusters and Favorable Immune Phenotypes in Young Breast Cancer Patients.
    Ingebriktsen LM; Svanøe AA; Myrmel Sæle AK; Humlevik ROC; Toska K; Kalvenes MB; Aas T; Heie A; Askeland C; Knutsvik G; Stefansson IM; Akslen LA; Hoivik EA; Wik E
    Mod Pathol; 2024 Aug; 37(8):100529. PubMed ID: 38810731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
    Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
    Front Immunol; 2020; 11():560074. PubMed ID: 33304345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
    BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer.
    Ingebriktsen LM; Finne K; Akslen LA; Wik E
    Br J Cancer; 2022 Nov; 127(10):1865-1875. PubMed ID: 35995935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
    Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
    Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study.
    Phakathi B; Dix-Peek T; Van Den Berg E; Dickens C; Nietz S; Cubasch H; Joffe M; Neugut AI; Jacobson JS; Ruff P; Duarte R
    Breast Cancer Res Treat; 2023 Aug; 200(3):337-346. PubMed ID: 37266756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying subtypes and developing prognostic models based on N6-methyladenosine and immune microenvironment related genes in breast cancer.
    Wang L; Li J; Mei N; Chen H; Niu L; He J; Wang R
    Sci Rep; 2024 Jul; 14(1):16586. PubMed ID: 39020010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated expression of Aurora-A/AURKA in breast cancer associates with younger age and aggressive features.
    Ingebriktsen LM; Humlevik ROC; Svanøe AA; Sæle AKM; Winge I; Toska K; Kalvenes MB; Davidsen B; Heie A; Knutsvik G; Askeland C; Stefansson IM; Hoivik EA; Akslen LA; Wik E
    Breast Cancer Res; 2024 Aug; 26(1):126. PubMed ID: 39198859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Molecular Analyses of an M2-Like Tumor-Associated Macrophage for Predicting the Prognosis and Immunotherapy in Breast Cancer.
    Chang K; Yue Q; Jin L; Fan P; Liu Y; Cao F; Zhang Y
    J Immunother; 2024 Jul-Aug 01; 47(6):205-215. PubMed ID: 38686904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of early menarche with breast tumor molecular features and recurrence.
    Harris AR; Wang T; Heng YJ; Baker GM; Le PA; Wang J; Ambrosone C; Brufsky A; Couch FJ; Modugno F; Scott CG; Vachon CM; Hankinson SE; Rosner BA; Tamimi RM; Peng C; Eliassen AH
    Breast Cancer Res; 2024 Jun; 26(1):102. PubMed ID: 38886818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
    Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
    BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
    Klopfenstein Q; Derangère V; Arnould L; Thibaudin M; Limagne E; Ghiringhelli F; Truntzer C; Ladoire S
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
    Filipits M; Nielsen TO; Rudas M; Greil R; Stöger H; Jakesz R; Bago-Horvath Z; Dietze O; Regitnig P; Gruber-Rossipal C; Müller-Holzner E; Singer CF; Mlineritsch B; Dubsky P; Bauernhofer T; Hubalek M; Knauer M; Trapl H; Fesl C; Schaper C; Ferree S; Liu S; Cowens JW; Gnant M;
    Clin Cancer Res; 2014 Mar; 20(5):1298-305. PubMed ID: 24520097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer.
    Li CI; Zhang Y; Cieślik M; Wu YM; Xiao L; Cobain E; Tang MC; Cao X; Porter P; Guenthoer J; Robinson DR; Chinnaiyan AM
    Clin Cancer Res; 2021 Jun; 27(11):3079-3093. PubMed ID: 33753452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
    Aure MR; Vitelli V; Jernström S; Kumar S; Krohn M; Due EU; Haukaas TH; Leivonen SK; Vollan HK; Lüders T; Rødland E; Vaske CJ; Zhao W; Møller EK; Nord S; Giskeødegård GF; Bathen TF; Caldas C; Tramm T; Alsner J; Overgaard J; Geisler J; Bukholm IR; Naume B; Schlichting E; Sauer T; Mills GB; Kåresen R; Mælandsmo GM; Lingjærde OC; Frigessi A; Kristensen VN; Børresen-Dale AL; Sahlberg KK;
    Breast Cancer Res; 2017 Mar; 19(1):44. PubMed ID: 28356166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.
    Jenkins EO; Deal AM; Anders CK; Prat A; Perou CM; Carey LA; Muss HB
    Oncologist; 2014 Oct; 19(10):1076-83. PubMed ID: 25142841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.